In addition, we documented the therapeutic efficacy of NLOC-015A, a multitarget small-molecule inhibitor of EGFR/MAP2K1/mTOR/YAP1 against NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.